Novartis to Acquire Neuroscience Company Cadent for Up to $770 Million
December 17 2020 - 2:45AM
Dow Jones News
By Olivia Bugault
Novartis AG said Thursday that it has entered into an agreement
for the acquisition of Massachusetts-based neuroscience company
Cadent Therapeutics.
Cadent will receive $210 million upfront and up to $560 million
in milestone payments, for a potential total of $770 million,
Cadent Therapeutics said in a separate statement on Thursday.
"The acquisition adds two new clinical stage programs to the
Novartis neuroscience portfolio, one for schizophrenia and the
other for movement disorders," the pharmaceutical giant said. The
acquisition also includes MIJ821, a clinical stage molecule that
Novartis licensed exclusively from Cadent in 2015 for
treatment-resistant depression.
With the acquisition, Novartis wants to make progress in
developing potential neuropsychiatric medicines, it said.
The deal should close during the first quarter of 2021, Novartis
said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 17, 2020 02:30 ET (07:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024